A NEW report, commissioned by GSK, reveals that increasing investment in adult immunisation could generate $1.1 billion in annual economic benefits.
The report, Prevention: A Productivity Superpower, launched at Parliament House in Canberra this week, shows that every dollar spent vaccinating adults against common illnesses yields a $3.50 economic return by reducing demands on healthcare, govt services, and carers, while boosting workplace productivity and improving life expectancy.
Conducted by Evaluate Consulting, the study highlights the cost-effectiveness of preventing diseases like shingles, influenza, and respiratory syncytial virus (RSV).
Vaccinating adults aged 50 and over for shingles could yield an annual $152 million return, influenza vaccinations could bring $303 million, and vaccinating high-risk individuals aged 60-74 for RSV could deliver $687 million annually.
Saul Eslake, an independent economist, described immunisation as "one of the most economically effective public health measures, second only to clean water".
He added, "as the population ages, vaccinations become even more valuable by helping Australians to live well for longer".
A public health physician, A/Prof John Litt emphasised the need to ensure all Australians, regardless of location or economic status, have access to vaccinations.
"Under-investment in vaccination disproportionately affects our most disadvantaged communities," he said, urging for enhanced vaccine access to secure Australia's health and economic future.
GSK Australia's Executive Country Medical Director, Dr Alan Paul, said the report aims to guide government decisions on healthcare investment.
"This report is designed to help government make decisions that ensure economic sustainability," Paul added.
The report calls for reforms to prioritise adult immunisation within the National Immunisation Program, advocating for a 95% vaccination target for adults, similar to the childhood program, and for increased public awareness around its benefits. JG
The above article was sent to subscribers in Pharmacy Daily's issue from 09 Oct 24
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 09 Oct 24
